Healthcare / BiotechnologyShenzhen
$39.67
-0.41 (-1.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-17.5M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.6B
P/E
38.1x
↑EV/EBITDA
24.1x
↑ROE
6.2%
↑Gross Margin
91.2%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+20.9%
FCF CAGR
—
FCF margin
18.0%
FCF / Net income
0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $838.1M · net income $165.6M · FCF $150.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $838.1M | $838.1M | $645.0M | $543.7M | $474.4M |
| Net Income | $165.6M | $165.6M | $123.8M | $153.6M | $203.7M |
| EBITDA | $240.2M | $240.2M | $181.7M | $205.4M | $252.4M |
| EPS | 0.99 | 0.99 | 0.74 | 0.91 | 1.21 |
| Gross Margin | 91.2% | 91.2% | 90.9% | 91.3% | 92.5% |
| Operating Margin | 23.5% | 23.5% | 16.9% | 24.4% | 34.9% |
| Net Margin | 19.8% | 19.8% | 19.2% | 28.3% | 42.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.05 | 0.02 | 0.03 |
| Current Ratio | 13.30 | 13.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $150.7M | $150.7M | $-82.6M | $-17.5M | $-82.1M |
| Returns | |||||
| ROE | 6.2% | 6.2% | 4.7% | 5.9% | 7.9% |
| Valuation | |||||
| P/E | 38.14 | 38.14 | 43.11 | 43.09 | 46.88 |
| EV/EBITDA | 24.08 | 24.08 | 19.76 | 22.88 | 30.88 |
| P/B | 2.50 | 2.50 | 2.04 | 2.56 | 3.73 |
| Growth & Yield | |||||
| Revenue Growth | 29.9% | 29.9% | 18.6% | 14.6% | — |
| EPS Growth | 34.0% | 34.0% | -19.3% | -24.6% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
52.7%
EPS terminal req.
$3.52
Spread vs growth
-18.7%
5Y implied EPS CAGR
33.9%
EPS terminal req.
$4.26
Spread vs growth
0.1%
10Y implied EPS CAGR
21.4%
EPS terminal req.
$6.86
Spread vs growth
12.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+12.9%
Start / end P/E
48.2x → 40.1x
EPS bridge
0.74 → 0.99
Residual
-5.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.